Stocks to watch: Hindalco, Dixon Tech, BEL, RVNL, Power Grid among shares in focus today
Shares of Hindalco, EIH, Zydus Lifesciences and Dixon Technologies will remain in focus as companies are set to post their Q4 earnings today.
Bharat Electronics Ltd (BEL), a government-owned enterprise, reported its Q4FY25 results, posting an 18% increase in net profit to ₹ 2,127 crore.
The company has been selected as the lowest bidder for a project valued at ₹ 178.64 crore awarded by IRCON International. The scope of the project includes supplying signalling, telecommunications, and EIMWB materials, as well as carrying out the installation, testing, and commissioning of distributed or centralised electronic interlocking (EI) systems at 10 newly developed stations.
Power Grid Corporation released its Q4 FY25 results, reporting a slight decline of 0.6% in net profit, which stood at ₹ 4,143 crore for the quarter.
The real estate giant posted a 36.3% year-on-year increase in net profit, reaching ₹ 1,282.2 crore in the fourth quarter, compared to ₹ 920.7 crore in Q4FY23.
The company posted a 23.4% increase in consolidated net profit on a quarterly basis, reaching ₹ 1,070.2 crore for the fourth quarter ended March 31, up from ₹ 867 crore in the preceding quarter.
A leading producer of glassware and laboratory equipment reported a 120% year-on-year increase in net profit for the fourth quarter of FY25, reaching ₹ 11 crore, up from ₹ 5 crore in the corresponding period last year.
Waaree Energies announced that its board has given the green light to a proposal to acquire Kamath Transformers Private Ltd for approximately ₹ 293 crore. Kamath Transformers specializes in the production of transformers.
The fair trade watchdog, the Competition Commission of India (CCI), has rejected a complaint accusing public sector lender Canara Bank of abusing its dominant position and engaging in anti-competitive practices concerning several loan deals.
The company announced a 7% decline in its Q4 net profit, which stood at ₹ 177.5 crore compared to ₹ 191 crore in the corresponding quarter of the previous fiscal year.
Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
14 hours ago
- Time of India
Hindalco Share Price Live Updates: Hindalco's Stock Price Update
04 Jun 2025 | 08:43:02 AM IST Stay informed with the Hindalco Stock Liveblog, your comprehensive resource for real-time updates and in-depth analysis of a leading stock. Get the latest details on Hindalco, including: Last traded price 632.0, Market capitalization: 142024.72, Volume: 3783426, Price-to-earnings ratio 8.88, Earnings per share 71.2. Our liveblog combines fundamental and technical insights to provide a holistic view of Hindalco's performance. Stay ahead of the market with breaking news that can influence Hindalco's trajectory. Our expert analysis and stock recommendations empower you to make well-informed financial decisions. Trust the Hindalco Stock Liveblog for up-to-date information and expert insights. The data points are updated as on 08:43:01 AM IST, 04 Jun 2025 Show more
Time of India
15 hours ago
- Time of India
Zydus acquires US biologics manufacturing facilities, Manufacturing News, ET Manufacturing
Advt Homegrown pharma major Zydus Lifesciences on Tuesday announced it has entered the global biologics contract development and manufacturing ( CDMO ) space with the acquisition of two manufacturing facilities from US-based Agenus Inc. The company will pay $75 million upfront and up to $50 million in milestone-linked payments over three deal gives Zydus control of biologics manufacturing units in Emeryville and Berkeley California , providing immediate access to advanced development and production capabilities. The facilities will be housed under an independent CDMO entity within the group and serve global biotech and pharma firms. Zydus intends to further expand the team and help create new jobs in the region and contribute to the local will also become the exclusive contract manufacturer for Agenus' two Phase 3-ready immuno-oncology candidates-Botensilimab and Balstilimab-for clinical and commercial supply. It has also secured the first right of negotiation to manufacture future Agenus pipeline Sharvil Patel, managing director, Zydus Lifesciences, said, "The acquisition gives Zydus a strategic foothold in the US for biologics manufacturing in the global hub for biotech innovation, California. It will enhance our ability to partner with innovation-centric entities, advancing new products and prioritizing patient-centric solutions. This move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry."The deal positions Zydus to benefit from growing global demand for biologics manufacturing, as governments and companies shift supply chains closer to key markets.
Indian Express
a day ago
- Indian Express
Zydus announces plan to acquire US manufacturing units of Agenus Inc
Zydus Lifesciences on Tuesday announced its plan to acquire Agenus Inc's US-based biologics CMC (Chemistry, Manufacturing, and Control) facilities, marking the Gujarat-based firm's entry into the global biologics contract development and manufacturing organisation (CDMO) business. Agenus Inc. is a clinical-stage immuno-oncology company developing immune therapies, which effectively combat cancer. Zydus, in a statement, said it is set to acquire two biologics manufacturing facilities, located in Emeryville and Berkeley, California, for an upfront consideration of USD 75 million and contingent payment of USD 50 million to be paid over three years, 'subject to achievement of certain revenue milestones'. With this acquisition, Zydus claims it will become a one-stop solution provider across the entire development spectrum of biologics, right from preclinical to toxicology studies, clinical development and now manufacturing. Zydus's CDMO business will operate as an independent entity and will house the acquired manufacturing capabilities, according to the statement. Further, Zydus will also become an exclusive contract manufacturer for Agenus and will provide manufacturing services for clinical and commercial supply of two identified Phase-3 ready immuno-oncology products, Botensilimab (BOT) and Balstilimab (BAL). In addition, Zydus will have the first right of negotiation to manufacture any of the future pipeline products developed by Agenus, the statement further read. Dr Sharvil Patel, Managing Director (MD) of Zydus Lifesciences, said, 'The acquisition will give Zydus a strategic foothold in the US for biologics manufacturing in the global hub for biotech innovation, California. It will enhance our ability to partner with innovation-centric entities, advancing new products and prioritising patient-centric solutions. This move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry.'
